Soleno Therapeutics, Inc. (SLNO)
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of rare diseases with high unmet need. Its lead candidate, DCCR (diazoxide choline extended-release), is being developed for the treatment of Prader-Willi syndrome (PWS), a complex genetic disorder with no FDA-approved treatment for its most severe symptoms. Soleno aims to become a leader in rare neuroendocrine conditions.
The company’s clinical results from its DESTINY PWS trials have shown promising outcomes in reducing hyperphagia—an uncontrollable hunger associated with PWS. DCCR has also demonstrated positive behavioral and metabolic improvements, positioning it as a potential breakthrough therapy. Soleno is engaging with the FDA for a potential regulatory path and preparing for commercialization pending approval.
Soleno’s value proposition lies in its singular focus, strong clinical data, and the potential for orphan drug exclusivity. Investor attention is building around upcoming regulatory milestones, which could rapidly shift the company’s profile from development-stage to commercial readiness. With a well-defined niche and validated science, Soleno is on the radar of rare disease investors. Chart
Follow Trade Ideas on 